FDA Shakeout: What’s Behind the Mass Exodus?

The latest departure from the Food and Drug Administration (FDA) is Dr. Tracy Beth Høeg, acting director of the Center for Drug Evaluation and Research, who left her post just days after FDA Commissioner Marty Makary resigned. This marks the third high-profile exit in as many weeks, leading to speculation about a brain drain within the agency.

Dr. Høeg’s tenure was marked by controversy over her motives behind challenging agency decisions. Her pushback against the fast-tracking of Sanofi’s teplizumab diabetes drug sparked concerns about pharmaceutical company influence on regulatory decisions. In June 2022, Reuters reported that Høeg raised safety questions about FDA-approved treatments for respiratory syncytial virus (RSV) in infants.

The pattern of behavior raises important questions about accountability within the agency. Regulators must ensure their decisions are based on science and not swayed by external pressures. The public’s trust in the FDA is paramount, and Høeg’s actions have eroded this trust. Her willingness to challenge established procedures and policies has created an environment of uncertainty.

Dr. Høeg’s departure follows a tumultuous period in FDA history, marked by significant changes under the Trump administration. Many high-profile departures and resignations occurred during this time. The recent overhaul of the childhood vaccine schedule, co-written by Høeg, was met with resistance from experts and the medical community. Her arguments about reducing aluminum exposure may have resonated with some, but they contradict nearly a century of evidence demonstrating the safety of vaccine ingredients.

Dr. Høeg’s own background – as a sports medicine doctor and dual citizen of the US and Denmark – has raised eyebrows. The assertion that fewer universal vaccines would reduce aluminum exposure is at odds with established science on vaccine safety.

The mass exodus from the FDA raises pressing questions about the future of food and drug regulation in the US. As the agency grapples with internal power struggles, external pressures, and conflicting priorities, one wonders if this is a symptom of a deeper problem within the administration. The lack of clear leadership has created an environment where regulators feel emboldened to challenge established policies.

The FDA’s primary responsibility is ensuring public health and safety through effective regulation. As we navigate this tumultuous period in agency history, it’s essential to remember that regulatory decisions have real-world consequences. The departure of Dr. Høeg and Commissioner Makary serves as a stark reminder of these stakes.

The FDA shakeout serves as a wake-up call to all regulatory agencies: internal dynamics can have far-reaching implications for public health and safety. As we move forward, it’s essential to prioritize accountability, transparency, and clear leadership. The stakes are higher than ever before, and regulators, policymakers, and the public cannot afford to ignore this reality.

The departure of Dr. Høeg and Commissioner Makary has left a gaping void in leadership, but it also presents an opportunity for the agency to course-correct and refocus on its core mission – protecting public health and safety through effective regulation.